Quarterly ResultMay 8, 2026, 04:12 PM
Soligenix Halts Phase 3 CTCL Trial for Futility; Raises Going Concern Doubt
AI Summary
Soligenix, Inc. reported a net loss of $2.82 million for Q1 2026, a slight improvement from $2.95 million in Q1 2025, with basic and diluted net loss per share improving to $(0.28) from $(0.97). However, the company's cash and cash equivalents decreased to $6.03 million from $7.94 million at year-end 2025, and it raised substantial doubt about its ability to continue as a going concern due to insufficient cash for the next 12 months. This comes after the Data Monitoring Committee recommended halting the Phase 3 FLASH2 trial for HyBryte™ (SGX301) in CTCL due to futility in April 2026.
Key Highlights
- Phase 3 FLASH2 trial for HyBryte™ (SGX301) in CTCL halted for futility.
- Company raised substantial doubt about its ability to continue as a going concern.
- Q1 2026 net loss was $2.82 million, compared to $2.95 million in Q1 2025.
- Basic and diluted net loss per share improved to $(0.28) from $(0.97) YoY.
- Cash and cash equivalents decreased to $6.03 million from $7.94 million at Dec 31, 2025.
- Net cash used in operating activities increased to $2.36 million from $1.85 million YoY.
- Specialized BioTherapeutics segment reported a Q1 net loss of $1.69 million.
- $0.8 million capacity remains from Rodman ATM Sales Agreement as of May 1, 2026.